Cargando…
Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
BACKGROUND: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528081/ https://www.ncbi.nlm.nih.gov/pubmed/34671773 http://dx.doi.org/10.1101/2021.10.10.21264827 |
_version_ | 1784586187673960448 |
---|---|
author | Atmar, Robert L. Lyke, Kirsten E. Deming, Meagan E. Jackson, Lisa A. Branche, Angela R. El Sahly, Hana M. Rostad, Christina A. Martin, Judith M. Johnston, Christine Rupp, Richard E. Mulligan, Mark J. Brady, Rebecca C. Frenck, Robert W. Bäcker, Martín Kottkamp, Angelica C. Babu, Tara M. Rajakumar, Kumaravel Edupuganti, Srilatha Dobryzynski, David Posavad, Christine M. Archer, Janet I. Crandon, Sonja Nayak, Seema U. Szydlo, Daniel Zemanek, Jillian Dominguez Islas, Clara P. Brown, Elizabeth R. Suthar, Mehul S. McElrath, M. Juliana McDermott, Adrian B. O’Connell, Sarah E. Montefiori, David C. Eaton, Amanda Neuzil, Kathleen M. Stephens, David S. Roberts, Paul C. Beigel, John H. |
author_facet | Atmar, Robert L. Lyke, Kirsten E. Deming, Meagan E. Jackson, Lisa A. Branche, Angela R. El Sahly, Hana M. Rostad, Christina A. Martin, Judith M. Johnston, Christine Rupp, Richard E. Mulligan, Mark J. Brady, Rebecca C. Frenck, Robert W. Bäcker, Martín Kottkamp, Angelica C. Babu, Tara M. Rajakumar, Kumaravel Edupuganti, Srilatha Dobryzynski, David Posavad, Christine M. Archer, Janet I. Crandon, Sonja Nayak, Seema U. Szydlo, Daniel Zemanek, Jillian Dominguez Islas, Clara P. Brown, Elizabeth R. Suthar, Mehul S. McElrath, M. Juliana McDermott, Adrian B. O’Connell, Sarah E. Montefiori, David C. Eaton, Amanda Neuzil, Kathleen M. Stephens, David S. Roberts, Paul C. Beigel, John H. |
author_sort | Atmar, Robert L. |
collection | PubMed |
description | BACKGROUND: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen. METHODS: In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×10(10) virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29. RESULTS: 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 153 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2–76-fold) and binding antibody titers (4.6–56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2–20-fold whereas heterologous boost increased titers 6.2–76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations. CONCLUSION: Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. |
format | Online Article Text |
id | pubmed-8528081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-85280812021-10-21 Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report Atmar, Robert L. Lyke, Kirsten E. Deming, Meagan E. Jackson, Lisa A. Branche, Angela R. El Sahly, Hana M. Rostad, Christina A. Martin, Judith M. Johnston, Christine Rupp, Richard E. Mulligan, Mark J. Brady, Rebecca C. Frenck, Robert W. Bäcker, Martín Kottkamp, Angelica C. Babu, Tara M. Rajakumar, Kumaravel Edupuganti, Srilatha Dobryzynski, David Posavad, Christine M. Archer, Janet I. Crandon, Sonja Nayak, Seema U. Szydlo, Daniel Zemanek, Jillian Dominguez Islas, Clara P. Brown, Elizabeth R. Suthar, Mehul S. McElrath, M. Juliana McDermott, Adrian B. O’Connell, Sarah E. Montefiori, David C. Eaton, Amanda Neuzil, Kathleen M. Stephens, David S. Roberts, Paul C. Beigel, John H. medRxiv Article BACKGROUND: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen. METHODS: In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×10(10) virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29. RESULTS: 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 153 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2–76-fold) and binding antibody titers (4.6–56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2–20-fold whereas heterologous boost increased titers 6.2–76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations. CONCLUSION: Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. Cold Spring Harbor Laboratory 2021-10-15 /pmc/articles/PMC8528081/ /pubmed/34671773 http://dx.doi.org/10.1101/2021.10.10.21264827 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Atmar, Robert L. Lyke, Kirsten E. Deming, Meagan E. Jackson, Lisa A. Branche, Angela R. El Sahly, Hana M. Rostad, Christina A. Martin, Judith M. Johnston, Christine Rupp, Richard E. Mulligan, Mark J. Brady, Rebecca C. Frenck, Robert W. Bäcker, Martín Kottkamp, Angelica C. Babu, Tara M. Rajakumar, Kumaravel Edupuganti, Srilatha Dobryzynski, David Posavad, Christine M. Archer, Janet I. Crandon, Sonja Nayak, Seema U. Szydlo, Daniel Zemanek, Jillian Dominguez Islas, Clara P. Brown, Elizabeth R. Suthar, Mehul S. McElrath, M. Juliana McDermott, Adrian B. O’Connell, Sarah E. Montefiori, David C. Eaton, Amanda Neuzil, Kathleen M. Stephens, David S. Roberts, Paul C. Beigel, John H. Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report |
title | Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report |
title_full | Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report |
title_fullStr | Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report |
title_full_unstemmed | Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report |
title_short | Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report |
title_sort | heterologous sars-cov-2 booster vaccinations – preliminary report |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528081/ https://www.ncbi.nlm.nih.gov/pubmed/34671773 http://dx.doi.org/10.1101/2021.10.10.21264827 |
work_keys_str_mv | AT atmarrobertl heterologoussarscov2boostervaccinationspreliminaryreport AT lykekirstene heterologoussarscov2boostervaccinationspreliminaryreport AT demingmeagane heterologoussarscov2boostervaccinationspreliminaryreport AT jacksonlisaa heterologoussarscov2boostervaccinationspreliminaryreport AT brancheangelar heterologoussarscov2boostervaccinationspreliminaryreport AT elsahlyhanam heterologoussarscov2boostervaccinationspreliminaryreport AT rostadchristinaa heterologoussarscov2boostervaccinationspreliminaryreport AT martinjudithm heterologoussarscov2boostervaccinationspreliminaryreport AT johnstonchristine heterologoussarscov2boostervaccinationspreliminaryreport AT ruppricharde heterologoussarscov2boostervaccinationspreliminaryreport AT mulliganmarkj heterologoussarscov2boostervaccinationspreliminaryreport AT bradyrebeccac heterologoussarscov2boostervaccinationspreliminaryreport AT frenckrobertw heterologoussarscov2boostervaccinationspreliminaryreport AT backermartin heterologoussarscov2boostervaccinationspreliminaryreport AT kottkampangelicac heterologoussarscov2boostervaccinationspreliminaryreport AT babutaram heterologoussarscov2boostervaccinationspreliminaryreport AT rajakumarkumaravel heterologoussarscov2boostervaccinationspreliminaryreport AT edupugantisrilatha heterologoussarscov2boostervaccinationspreliminaryreport AT dobryzynskidavid heterologoussarscov2boostervaccinationspreliminaryreport AT posavadchristinem heterologoussarscov2boostervaccinationspreliminaryreport AT archerjaneti heterologoussarscov2boostervaccinationspreliminaryreport AT crandonsonja heterologoussarscov2boostervaccinationspreliminaryreport AT nayakseemau heterologoussarscov2boostervaccinationspreliminaryreport AT szydlodaniel heterologoussarscov2boostervaccinationspreliminaryreport AT zemanekjillian heterologoussarscov2boostervaccinationspreliminaryreport AT dominguezislasclarap heterologoussarscov2boostervaccinationspreliminaryreport AT brownelizabethr heterologoussarscov2boostervaccinationspreliminaryreport AT sutharmehuls heterologoussarscov2boostervaccinationspreliminaryreport AT mcelrathmjuliana heterologoussarscov2boostervaccinationspreliminaryreport AT mcdermottadrianb heterologoussarscov2boostervaccinationspreliminaryreport AT oconnellsarahe heterologoussarscov2boostervaccinationspreliminaryreport AT montefioridavidc heterologoussarscov2boostervaccinationspreliminaryreport AT eatonamanda heterologoussarscov2boostervaccinationspreliminaryreport AT neuzilkathleenm heterologoussarscov2boostervaccinationspreliminaryreport AT stephensdavids heterologoussarscov2boostervaccinationspreliminaryreport AT robertspaulc heterologoussarscov2boostervaccinationspreliminaryreport AT beigeljohnh heterologoussarscov2boostervaccinationspreliminaryreport AT heterologoussarscov2boostervaccinationspreliminaryreport |